Furthermore, tumor cells utilize glycolysis promoted by FTO to inhibit the activation and effector states of CD8+ T cells, which can be reversed by combining an FTO inhibitor with anti-PD-L1 blockade [268]. Here, CD274 is linked to neoplasm.